

United States Patent and Trademark Office



W

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: GOMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Vigniia 22313-1450 www.uspto.gov

APPLICATION NO.	F	ILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO	
09/852,804	05/11/2001		Takao Kasai	0445-0299P	5485	
2292	7590	06/16/2003				
	EWART KOLASCH & BIRCH EXAMINER				VER	
PO BOX 74 FALLS CH		CH, VA 22040-0747		STEPHENS, JACQUELINE F		
				ART UNIT	PAPER NUMBER	
				3761	. 1	
				DATE MAILED: 06/16/2003	1/1	

Please find below and/or attached an Office communication concerning this application or proceeding.

R.	C
----	---

Advisory	Action
7.41.00.y	,

Application No.	Applicant(s)	
09/852,804	KASAI ET AL.	
Examiner	Art Unit	
Jacqueline F Stephens	3761	

--The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

THE REPLY FILED 02 June 2003 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE. Therefore, further action by the applicant is required to avoid abandonment of this application. A proper reply to a final rejection under 37 CFR 1.113 may only be either: (1) a timely filed amendment which places the application in condition for allowance; (2) a timely filed Notice of Appeal (with appeal fee); or (3) a timely filed Request for Continued Examination (RCE) in compliance with 37 CFR 1.114.

condition for allowance; (2) a timely filed Notice of Appeal (with appeal fee); or (3) a timely filed Request for Continued Examination (RCE) in compliance with 37 CFR 1.114.
PERIOD FOR REPLY [check either a) or b)]
a) \boxtimes The period for reply expires <u>5</u> months from the mailing date of the final rejection.
b) The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection. ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f).
Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).
1. A Notice of Appeal was filed on Appellant's Brief must be filed within the period set forth in 37 CFR 1.192(a), or any extension thereof (37 CFR 1.191(d)), to avoid dismissal of the appeal.
2. The proposed amendment(s) will not be entered because:
(a) ☐ they raise new issues that would require further consideration and/or search (see NOTE below);
(b) they raise the issue of new matter (see Note below);
(c) ☐ they are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or
(d) they present additional claims without canceling a corresponding number of finally rejected claims.NOTE:
3. Applicant's reply has overcome the following rejection(s):
4. Newly proposed or amended claim(s) would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s).
5. ☑ The a) ☑ affidavit, b) ☐ exhibit, or c) ☐ request for reconsideration has been considered but does NOT place the application in condition for allowance because: See Continuation Sheet.
6. The affidavit or exhibit will NOT be considered because it is not directed SOLELY to issues which were newly raised by the Examiner in the final rejection.
7.⊠ For purposes of Appeal, the proposed amendment(s) a)⊠ will not be entered or b) will be entered and an explanation of how the new or amended claims would be rejected is provided below or appended.
The status of the claim(s) is (or will be) as follows:
Claim(s) allowed:
Claim(s) objected to:
Claim(s) rejected: <u>1-14</u> .
Claim(s) withdrawn from consideration:
8. The proposed drawing correction filed on is a) approved or b) disapproved by the Examiner.
9.⊠ Note the attached Information Disclosure Statement(s)(PTO-1449) Paper No(s). 9. 10.□ Other:
WEILUN LO
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 3700

U.S. Patent and Trademark Office



and declaration filed 6/2/03 has been fully considered but is not persuasive. Applicant argues Paul does not teach the expedient of an agent having a skin-care effect and having substantially no decomposing action on the superabsorbent polymer. Applicant has shown in the declaration that the concentration of zinc sulfate used with a super absorbent polymer has an inverse relationship to the water absorption capacity. However, the language in independent claim 1 requires the agent have 'susbtantially no decomposing action' on the superabsorbent polymer. It stands to reason that the greater the amount of a non-water absorbing agent added to a product, the less water absorbent capacity the product will have. This does not nevertheless indicate the water-absorbing component is actually being decomposed, rather that it is hindered in its capability to absorb water. Paul teaches an absorbent article comprising an agent having a skin-care effect and the absorbent article has a superabsorbent polymer with a water absorption capacity within the claimed range of the water absorption capacity of dependent claim 4. While the skin care agent, if added in exorbitant amounts, may affect the water absorption capacity of the superabsorbent polymer, it has not been proven that the agent actually decomposes the superabsorbent polymer. Additionally, since the invention of Paul has the claimed water absorption capacity, it is understood the concentration of the agent used is appropriate for the intended use of the article.